Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma

• Autorzy: Opalińska Marta , Sowa-Staszczak Anna , Al Maraih Ibraheem , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Identyfikatory

DOI

10.1515/bams-2021-0138

• Języki publikacji: EN

Abstrakty

EN

Objectives: Severe hypoglycemia in a course of inoperable insulinoma may be life-threating and often it is not well controlled, even by high doses of diazoxide requiring second line treatment. Among available methods PRRT is characterized by relatively low toxicity and is connected with favorable antitumor effect. The aim of the study was an evaluation of the PRRT effectiveness in control of hypoglycemia in patients with primary inoperable insulinoma. Methods: Three patients (female with metastatic insulinoma,male with primaryinoperable pancreatic tumor, female with MEN1 syndrome and hepatic metastases) were treated with PRRT due to severe hypoglycemia poorly controlled by diazoxide in course of primary inoperable insulinoma. Results: Patient 1 baseline fasting glucose concentration increased from 2.4 mmol/L [3.30-5.60] to 5.9 mmol/L after PRRT. In patient 2 fasting glucose level 2.30 mmol/L increased after PRRT to 7.0 mmol/L, while baseline insulin level initially 31.15 uU/mL [2.6–24.9] decreased to 15.4 uU/mL. In patients 3, baseline fasting glucose level 2.5 mmol/L increased after PRRT to 7.9 mmol/L, and insulin decreased from 57.9 uU/mL to 6.3 uU/mL. In imaging there was partial response (PR) in patient 1 and 2 and stabilization of the tumor size in patient 3. In patient 2 reduction of tumor infiltration let for curative surgery performed 4 months after PPRT. Conclusions: PRRT may be effective as a first or second line treatment in management of hypoglycemia for patients with hormonally active inoperable insulinoma.

Słowa kluczowe

EN

diazoxide; hypoglycemia; insulinoma; NET; neuroendocrine tumors; PRRT

• Wydawca: Uniwersytet Jagielloński - Collegium Medicum ; Index Copernicus Sp. z o.o.
• Czasopismo: Bio-Algorithms and Med-Systems
• Rocznik: 2021
• Tom: Vol. 17, no. 4
• Strony: 221--226
• Opis fizyczny: Bibliogr. 28 poz., tab., wykr.

Twórcy

autor

Opalińska Marta

• Nuclear Medicine Unit, Department of Endocrinology, Oncological Endocrinology and Nuclear Medicine, University Hospital, Kraków, Poland

• https://orcid.org/0000-0002-5919-9291

autor

Sowa-Staszczak Anna

• Department of Endocrinology, Jagiellonian University Medical College, ul. Św. Anny 12, 31-501 Kraków, Poland, Phone: [phone]

autor

Al Maraih Ibraheem

• Nuclear Medicine Unit, Department of Endocrinology, Oncological Endocrinology and Nuclear Medicine, University Hospital, Kraków, Poland

autor

Gilis-Januszewska Aleksandra

• Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland

autor

Hubalewska-Dydejczyk Alicja

• Chair and Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland

Bibliografia

• 1. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153-71.
• 2. Hofland J, Feelders RA, Brabander T, Franssen GJH, de Herder WW. Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. Neth J Med 2018;76:100-8.
• 3. de Herder WW, Zandee WT, Hofland J. Insulinoma. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000, PMID:25905215 p.
• 4. Kunikowska J, Słodkowski M, Koperski Ł, Kolasa A, Maryański J, Pawliszak P, et al. Radioguided surgery in patient with pancreatic neuroendocrine tumour followed by PET/CT scan as a new approach of complete resection evaluation-case report. Nucl Med Rev Cent East Eur 2014;17:110-4.
• 5. Brand C, Abdel-Atti D, Zhang Y, Carlin S, Clardy SM, Keliher EJ, et al. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjug Chem 2014;25: 1323-30.
• 6. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43:675-86.
• 7. Guo Q, Wu Y. Surgical treatment of pancreatic islet cell tumor: report of 44 cases. Hepato-Gastroenterology 2013;60:2099-102.
• 8. Niitsu Y, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Satou F, et al. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J 2019;66:149-55.
• 9. Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev 2020;41:371-403.
• 10. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. ESMO Guidelines Committee. Electronic address: [e-mail]. Ann Oncol 2020;31:844-60.
• 11. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imag 2013;40:800-16.
• 12. Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci 2020;21:1682.
• 13. Veltroni A, Cosaro E, Spada F, Fazio N, Faggiano A, Colao A, et al. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol 2020;182:439-46.
• 14. Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, et al. Carcinoid syndrome and hyperinsulinemic hypoglycemia associated with neuroendocrine neoplasms: a critical review on clinical and pharmacological management. Pharmaceuticals 2021;14:539.
• 15. Gilis-Januszewska A, Bogusławska A, Hasse-Lazar K, JureckaLubieniecka B, Jarząb B, Sowa-Staszczak A, et al. Heterogeneity of the clinical presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) variant within a three-generation family. Genes 2021;12:512.
• 16. Bonin S, Stanta G. Pre-analytics and tumor heterogeneity. N Biotechnol 2020;55:30-5.
• 17. Mapelli P, Partelli S, Salgarello M, Doraku J, Muffatti F, Schiavo Lena M, et al. Dual tracer 68Ga-DOTATOC and 18F-FDG PET improve preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. Diagnostics 2021;11:192.
• 18. Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics 2020;10:1059.
• 19. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin re-ceptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and ra-diotherapeutic use. Eur J Nucl Med 2000; 27:273-82.
• 20. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20:716-31.
• 21. Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imag 2018;45:2318-27.
• 22. Sowa-Staszczak A, Trofimiuk-Müldner M, Stefańska A, Tomaszuk M, Buziak-Bereza M, Gilis-Januszewska A, et al. 99mTc labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma. PLoS One 2016;11:e0160714.
• 23. Christ E, Antwi K, Fani M, Wild D. Innovative imaging of insulinoma: the end of sampling? A review. Endocr Relat Cancer. 2020;27:R79-92.
• 24. Magalhães D, Sampaio IL, Ferreira G, Bogalho P, Martins-Branco D, Santos R, et al. Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Invest 2019;42:249-60.
• 25. Zandee WT, Brabander T, Blažević A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104: 1336-44.
• 26. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Lancet 2016;387:968-77.
• 27. Strosberg JR, Caplin ME, Knuz PL, Ruszniewski P, Bodei L, Hendifar AE, et al. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol 2021;39(15 Suppl): 4112.
• 28. Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights. OncoTargets Ther 2020;13:3545-55.

Uwagi

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).